Coloplast Crescita futura

Future criteri di controllo 3/6

Si prevede che Coloplast aumenterà gli utili e i ricavi rispettivamente del 11% e 7.7% all'anno, mentre si prevede che l'EPS crescerà del 11.2% all'anno.

Informazioni chiave

11.0%

Tasso di crescita degli utili

11.2%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	0%
Tasso di crescita dei ricavi	7.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	18 May 2023

Aggiornamenti recenti sulla crescita futura

Recent updates

Previsioni di crescita degli utili e dei ricavi

BMV:0QBO N - Stime future degli analisti e dati finanziari passati (DKK Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
9/30/2025	28,820	6,541	6,167	7,542	14
9/30/2024	26,707	5,885	5,587	6,879	17
9/30/2023	24,748	5,107	4,809	6,220	18
3/31/2023	24,074	4,801	3,663	4,894	N/A
12/31/2022	23,515	4,626	3,246	4,455	N/A
9/30/2022	22,579	4,706	3,964	5,099	N/A
6/30/2022	21,620	4,781	3,894	4,913	N/A
3/31/2022	20,606	4,746	3,735	4,712	N/A
12/31/2021	19,857	4,896	4,272	5,209	N/A
9/30/2021	19,426	4,825	3,324	5,290	N/A
6/30/2021	18,916	4,561	3,102	5,023	N/A
3/31/2021	18,500	4,304	3,162	5,077	N/A
12/31/2020	18,570	4,241	3,003	4,941	N/A
9/30/2020	18,544	4,197	3,828	4,759	N/A
6/30/2020	18,572	3,949	3,876	4,842	N/A
3/31/2020	18,752	4,020	3,872	4,764	N/A
12/31/2019	18,330	3,974	3,833	4,615	N/A
9/30/2019	17,939	3,873	3,667	4,357	N/A
6/30/2019	17,555	4,119	3,599	4,161	N/A
3/31/2019	17,181	3,999	3,562	4,177	N/A
12/31/2018	16,815	3,896	3,522	4,126	N/A
9/30/2018	16,449	3,845	3,692	4,361	N/A
6/30/2018	16,195	3,816	3,587	4,370	N/A
3/31/2018	15,882	3,778	3,361	4,111	N/A
12/31/2017	15,728	3,791	3,235	4,004	N/A
9/30/2017	15,528	3,797	2,566	3,251	N/A
6/30/2017	15,287	3,211	2,308	2,994	N/A
3/31/2017	15,061	3,279	1,808	2,492	N/A
12/31/2016	14,780	3,264	N/A	2,653	N/A
9/30/2016	14,681	3,143	N/A	3,028	N/A
6/30/2016	14,563	1,297	N/A	3,081	N/A
3/31/2016	14,417	1,028	N/A	3,568	N/A
12/31/2015	14,264	927	N/A	3,320	N/A
9/30/2015	13,909	899	N/A	3,337	N/A
6/30/2015	13,502	3,162	N/A	3,119	N/A
3/31/2015	13,096	3,241	N/A	3,015	N/A
12/31/2014	12,666	2,407	N/A	3,193	N/A
9/30/2014	12,428	2,390	N/A	3,149	N/A
6/30/2014	12,184	2,298	N/A	3,177	N/A
3/31/2014	12,008	2,220	N/A	3,074	N/A
12/31/2013	11,833	2,874	N/A	3,270	N/A
9/30/2013	11,635	2,711	N/A	3,136	N/A
6/30/2013	11,514	2,570	N/A	2,912	N/A
3/31/2013	11,384	2,448	N/A	2,907	N/A
12/31/2012	11,234	2,327	N/A	2,894	N/A
9/30/2012	11,023	2,194	N/A	2,649	N/A
6/30/2012	10,745	2,117	N/A	2,686	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di 0QBO N ( 11% all'anno) è superiore al tasso di risparmio ( 7.6% ).

Guadagni vs Mercato: Si prevede che gli utili di 0QBO N ( 11% all'anno) cresceranno più rapidamente del mercato MX ( 11.3% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di 0QBO N cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di 0QBO N ( 7.7% all'anno) crescerà più rapidamente del mercato MX ( 7.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di 0QBO N ( 7.7% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 0QBO N è previsto essere elevato tra 3 anni

Coloplast Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita